Takeda Pharmaceuticals International, Inc.
Takeda Pharmaceuticals International, Inc.
Explore linked clinical trials.2 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| SIZOMUS Safety of Ixazomib Targeting Plasma Cells in Multiple Sclerosis | CNS demyelinating autoimmune disease, Chronic Disease, Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, autoimmune disease, autoimmune disorder of the nervous system, chronic progressive multiple sclerosis, demyelinating disease, immune system disorder, multiple sclerosis, nervous system disorder, relapsing-remitting multiple sclerosis | Recruiting | Phase 1 | 2026-09-08 | NCT03783416 | |
| BEhavioral and Adherence Model for Improving Quality, Health Outcomes and Cost-Effectiveness of healthcaRe | Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Rare Diseases, cardiovascular disorder, neoplasm | Recruiting | Not applicable | 2026-04-01 | NCT06856902 |